BC. The relative risk of LC after treated BC ranges from 1.38 to 5.05. We hypothesized that genetic variants might predispose patients (Pts) to develop LC after BC. Our aim was to perform whole exome sequencing (WES) to identify genes associated with such predisposition. Method: 28 women who developed LC after BC (Study Population, SP) and 32 women treated for BC and with no secondary cancer after a follow-up 10 years (control population; CP) were enrolled. DNA was extracted from tumors and normal tissue samples from both SP and CP. Libraries were prepared with Agilent SureSelect All Exon kit and sequenced on Illumina HiSeq2500. Variant calling was performed with FreeBayes software. Result: The median age of SP at BC diagnosis was 63.5 years (range: 47-76); the median interval between diagnosis of BC and occurrence of LC was 4.5 years (range: 0-11). 13 Pts (46%) were never-smokers and, among the 21 Pts who had received aRT, 13 (62%) developed ipsilateral LC. At somatic analysis, no common mutation among known driver genes was shared between each BC and LC pair. WES performed on BC and LC samples identified two mutational signatures (S1 and S2). S1 (C>T substitutions) was observed in all BC samples and 16/28 (57%) LC samples and was more frequent in never-smokers (11 vs. 5 Pts) and among Pts who developed ipsilateral LC after aRT (10 vs. 6 Pts). S2 (C>A transversions) was observed in 12/28 LC samples (43%) and was strongly associated with smoking habit (10 vs. 2 Pts). When compared to COSMIC libraries, S2 resulted similar to COSMIC 4, common in LC samples collected from smokers. Since S1 was largely shared between paired BC and LC samples, we explored the eventuality of a genetic predisposition to S1-related malignancies with a gene-based burden test over rare germline variants in normal tissue of S1-LC Pts compared to CP Pts; 249 candidate genes were identified (FDR<0.05). Conclusion: Our data identify two mutational S underlying the LC development. Germline analysis suggests that genetic variants may contribute to increase the risk of LC after BC.
Background: Src family tyrosine kinases, including Fyn, are nonreceptor tyrosine kinases and they are known to drive malignancy in various kinds of cancers. Some papers have reported that Fyn is an effector of EGFR signaling. Additionally, Fyn is recognized as an additional therapeutic target. However, little is known about the clinical importance of phosphorylated Fyn (pFyn) in lung adenocarcinoma. The purpose of the present study is to clarify the prognostic significance of pFyn in lung adenocarcinoma. Method: A total of 251 lung adenocarcinoma specimens were collected from patients who underwent surgery in our institute. Tissue microarrays (TMA) were assembled from paraffin-embedded tumor blocks. We analyzed pFyn expression through immunostaining of TMA and classified them as 0, +1, +2, +3. The association between pFyn expression as well as the patients' clinical information was statistically analyzed. Correlations were compared using Pearson's chi-square test and overall survival (OS) were compared using the log-rank test after propensity score matching (age, gender, smoking history, pathological stage, EGFR mutation status, and p53 mutation status). The Institutional Review Board approved this study and informed consent for tumor tissue usage was obtained pre-operatively. Result: Unadjusted pathologic stage distributions by TNM classification (WHO, 7th edition) were as follows: Stage 1A: 128 patients, Stage 1B: 73, Stage 2A: 23, Stage 2B: 4, Stage 3A: 23. pFyn was positive in 118 cases (47.6%). There was a significant correlation between pFyn expression and gender, pathological stage, p53 mutation status, and poor OS. The propensity score adjusted analysis revealed that the prognosis of pFyn positive group was significantly worse compared to the pFyn negative group (p¼0.046), which was observed only in the patients with mutant EGFR. Conclusion: pFyn expression may affect the prognosis of patients with lung adenocarcinoma in a EGFR mutation dependent manner. Keywords: phosphorylated Fyn, Adenocarcinoma, EGFR mutation Background: Survival of patients with stage I non-small-cell lung cancer (NSCLC) was indicative of significant variability with biological complexity. In addition to repairing DNA damage, understanding for necroptosis as new mechanism of cell death is rapidly growing as one of the hallmark of cancer. Therefore, the development of a prognostic biomarker focusing on necroptosis and DNA damage is an intriguing issue. Method: Expression of eight proteins (RIPK3, MLKL, PELI1, P53, ATM, gH2AX, Chk2, and BRCA1) and overall survival were investigated in 394 pathological stage I NSCLC patients. Result: The proteins involved in necroptosis or DNA damage repair exhibited differential expression between squamous cell carcinoma and other histology. Low expression of RIPK3 showed a trend for having worse survival in the entire cohort. Analysis performed based on histology revealed that expression of RIPK3, PELI1, P53, or BRCA1 was an independent prognostic factor in squamous cell carcinoma patients (aHR, Cox P: 2.292, 0.008 for RIPK3; 2.007, 0.033 for PELI1; 0.391, 0.003 for P53; 2.088, 0.018 for BRCA1). When combined effect of RIPK3 or PELI1 with P53 or DNA damage repair proteins analyzed, the effect on survival is was markedly strengthened in squamous cell carcinoma patients. However, these effects were not detected in adenocarcinoma patients. Conclusion: Expression or their combination of proteins involved in necroptosis and DNA damage repair is an important determinant of survival in stage I squamous cell carcinoma patients.
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